Market Overview

UPDATE: Wedbush Securities Initiates Coronado Biosciences at Outperform on Outlook for CNDO-201

Related CNDO
Coronado Falls on TSO Study Results - Analyst Blog
Pipeline Progress at Coronado Biosciences - Analyst Blog

Wedbush Securities initiated coverage on Coronado Biosciences (NASDAQ: CNDO) with an Outperform rating and a $13 price target.

Wedbush Securities commented, "We believe that CNDO-201 is likely to find substantial use in the 40% of patients with inflammatory bowel disease (IBD) that fail last-line TNF-alpha therapy. Moreover, given the drawbacks and growing concerns about the safety of TNF-alpha's and corticosteroids, we believe that CNDO-201, driven by superior safety and tolerability, could displace TNF-alpha therapies and be used in combination with current first-line therapies in IBD, a market worth >$4 billion."

Coronado Biosciences closed at $4.79 on Wednesday.

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (CNDO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters